Skip to main content
Erschienen in: Diseases of the Colon & Rectum 11/2006

01.11.2006

Preoperative Chemoradiotherapy with Concomitant Small Field Boost Irradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Phase II Study (KROG 04-01)

verfasst von: Dae Yong Kim, M.D., Tae Hyun Kim, M.D., Kyung Hae Jung, M.D., Hee Jin Chang, M.D., Seok-Byung Lim, M.D., Hyo Seong Choi, M.D., Seung-Yong Jeong, M.D., Taek-Keun Nam, M.D., Seong Yeob Ryu, M.D., Doo Suk Lee, M.D., Sung Il Choi, M.D., Jin Hyung Kang, M.D., Sei-Chul Yoon, M.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Purpose

This study was designed to determine the effect of concomitant small field boost irradiation given during preoperative chemoradiotherapy for patients with locally advanced rectal cancer.

Methods

The study prospectively enrolled 38 patients scheduled for preoperative chemoradiotherapy. Pelvic radiotherapy of 43.2 Gy/24 fractions was delivered and boost radiotherapy of 7.2 Gy/12 fractions was concomitantly administered during the latter half of the pelvic radiotherapy treatment period. Two cycles of a bolus 5-fluorouracil and leucovorin injection in the first and fifth weeks of radiotherapy were administered. The median time to surgery after completion of chemoradiotherapy was six weeks. Tumor responses to chemoradiotherapy were assessed by using magnetic resonance volumetry and postchemoradiotherapy pathology tests to determine tumor downstaging and tumor regression rate.

Results

Thirty-six of 38 patients (94.7 percent) underwent the scheduled surgery. The mean tumor volume reduction rate was 70.3 percent, and the clinical response rate was 66.7 percent. The downstaging rates were 41.7 percent for T classification, 85.2 percent for N classification, and 72.2 percent for stage. Tumor regression grades after preoperative chemoradiotherapy were Grade 1 in 5 patients (13.9 percent), Grade 2 in 24 patients (66.7 percent), Grade 3 in 3 patients (8.3 percent), and Grade 4 in 4 patients (11.1 percent). Ten patients (26.3 percent) experienced ≥ Grade 3 acute toxicity.

Conclusions

Our data suggest that concomitant boost irradiation does not improve clinical outcomes compared with other published preoperative chemoradiotherapy regimens. In addition, the clinicians choosing to use concomitant small field boost irradiation should be cautious to minimize the risk of unplanned sphincter ablation.
Literatur
1.
Zurück zum Zitat Sauer, R, Becker, H, Hohenberger, W, et al. 2004Preoperative versus postoperative chemoradiotherapy for rectal cancerN Engl J Med35117311740PubMedCrossRef Sauer, R, Becker, H, Hohenberger, W,  et al. 2004Preoperative versus postoperative chemoradiotherapy for rectal cancerN Engl J Med35117311740PubMedCrossRef
2.
Zurück zum Zitat Gerard, JP, Chapet, O, Nemoz, C, et al. 2004Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: The Lyon R96-02 Randomized TrialJ Clin Oncol2224042909PubMedCrossRef Gerard, JP, Chapet, O, Nemoz, C,  et al. 2004Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: The Lyon R96-02 Randomized TrialJ Clin Oncol2224042909PubMedCrossRef
3.
Zurück zum Zitat Habr-Gama, A, Perez, RO, Nadalin, W, et al. 2005Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survivalJ Gastrointest Surg99099PubMedCrossRef Habr-Gama, A, Perez, RO, Nadalin, W,  et al. 2005Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survivalJ Gastrointest Surg99099PubMedCrossRef
4.
Zurück zum Zitat Vecchio, FM, Valentini, V, Minsky, BD, et al. 2005The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancerInt J Radiat Oncol Biol Phys62752760PubMedCrossRef Vecchio, FM, Valentini, V, Minsky, BD,  et al. 2005The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancerInt J Radiat Oncol Biol Phys62752760PubMedCrossRef
5.
Zurück zum Zitat Rodel, C, Martus, P, Papadoupolos, T, et al. 2005Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancerJ Clin Oncol2386888696PubMedCrossRef Rodel, C, Martus, P, Papadoupolos, T,  et al. 2005Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancerJ Clin Oncol2386888696PubMedCrossRef
6.
Zurück zum Zitat Chan, AK, Wong, A, Jenken, D, Heine, J, Buie, D, Johnson, D 2005Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapyInt J Radiat Oncol Biol Phys61665677PubMedCrossRef Chan, AK, Wong, A, Jenken, D, Heine, J, Buie, D, Johnson, D 2005Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapyInt J Radiat Oncol Biol Phys61665677PubMedCrossRef
7.
Zurück zum Zitat Hofheinz, RD, Gerstenberg-Helldorf, B, Wenz, F, et al. 2005Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancerJ Clin Oncol2313501357PubMedCrossRef Hofheinz, RD, Gerstenberg-Helldorf, B, Wenz, F,  et al. 2005Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancerJ Clin Oncol2313501357PubMedCrossRef
8.
Zurück zum Zitat Mehta, VK, Cho, C, Ford, JM, et al. 2003Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancerInt J Radiat Oncol Biol Phys55132137PubMedCrossRef Mehta, VK, Cho, C, Ford, JM,  et al. 2003Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancerInt J Radiat Oncol Biol Phys55132137PubMedCrossRef
9.
Zurück zum Zitat Chau, I, Brown, G, Cunningham, D, et al. 2006Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancerJ Clin Oncol24668674PubMedCrossRef Chau, I, Brown, G, Cunningham, D,  et al. 2006Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancerJ Clin Oncol24668674PubMedCrossRef
10.
Zurück zum Zitat Voelter, V, Stupp, R, Matter, M, et al. 2003Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I studyInt J Radiat Oncol Biol Phys5612881294PubMedCrossRef Voelter, V, Stupp, R, Matter, M,  et al. 2003Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I studyInt J Radiat Oncol Biol Phys5612881294PubMedCrossRef
11.
Zurück zum Zitat Mohiuddin, M, Winter, K, Mitchell, E, et al. 2006Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012J Clin Oncol24650655PubMedCrossRef Mohiuddin, M, Winter, K, Mitchell, E,  et al. 2006Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012J Clin Oncol24650655PubMedCrossRef
12.
Zurück zum Zitat Wiltshire, K, Brierley, J, Swallow, C, et al. 2004Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathological complete response, local recurrence free survival & disease free survivalInt J Radiat Oncol Biol Phys60(Suppl)293CrossRef Wiltshire, K, Brierley, J, Swallow, C,  et al. 2004Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathological complete response, local recurrence free survival & disease free survivalInt J Radiat Oncol Biol Phys60(Suppl)293CrossRef
13.
Zurück zum Zitat Kim, YH, Kim, DY, Kim, TH, et al. 2005Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancerInt J Radiat Oncol Biol Phys62761768PubMedCrossRef Kim, YH, Kim, DY, Kim, TH,  et al. 2005Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancerInt J Radiat Oncol Biol Phys62761768PubMedCrossRef
14.
Zurück zum Zitat Sobin, LH, Wittenkind, CH 2002International Union Against Cancer. TNM classification of malignant tumors6Wiley-LissNew York Sobin, LH, Wittenkind, CH 2002International Union Against Cancer. TNM classification of malignant tumors6Wiley-LissNew York
15.
Zurück zum Zitat Dworak, O, Keilholz, L, Hoffmann, A 1997Pathological features of rectal cancer after preoperative radiochemotherapyInt J Colorectal Dis121923PubMedCrossRef Dworak, O, Keilholz, L, Hoffmann, A 1997Pathological features of rectal cancer after preoperative radiochemotherapyInt J Colorectal Dis121923PubMedCrossRef
16.
Zurück zum Zitat Lim, SB, Heo, SC, Lee, MR, et al. 2005Changes in outcome with sphincter preserving surgery for rectal cancer in Korea, 1991–2000Eur J Surg Oncol31242249PubMedCrossRef Lim, SB, Heo, SC, Lee, MR,  et al. 2005Changes in outcome with sphincter preserving surgery for rectal cancer in Korea, 1991–2000Eur J Surg Oncol31242249PubMedCrossRef
17.
Zurück zum Zitat Therasse, P, Arbuck, SG, Eisenhauer, EA, et al. 2000New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst92205216PubMedCrossRef Therasse, P, Arbuck, SG, Eisenhauer, EA,  et al. 2000New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst92205216PubMedCrossRef
18.
Zurück zum Zitat Widder, J, Herbst, F, Dobrowsky, W, et al. 2005Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II)Br J Cancer9212091214PubMedCrossRef Widder, J, Herbst, F, Dobrowsky, W,  et al. 2005Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II)Br J Cancer9212091214PubMedCrossRef
19.
Zurück zum Zitat O’Connell, MJ, Martenson, JA, Wieand, HS, et al. 1994Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgeryN Engl J Med331502507PubMedCrossRef O’Connell, MJ, Martenson, JA, Wieand, HS,  et al. 1994Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgeryN Engl J Med331502507PubMedCrossRef
20.
Zurück zum Zitat Smalley, SR, Benedetti, J, Williamson, S, et al. 2004Intergroup 0144 a phase III rectal surgical adjuvant study of pelvic radiation (XRT) plus 5-FU based chemotherapy (bolus 5-FU before and after PVI + XRT vs. PVI before, during, and after XRT vs. biochemically modulated bolus 5-FU and XRT): mature outcome results and pelvic failure analysisInt J Radiat Oncol Biol Phys60137138CrossRef Smalley, SR, Benedetti, J, Williamson, S,  et al. 2004Intergroup 0144 a phase III rectal surgical adjuvant study of pelvic radiation (XRT) plus 5-FU based chemotherapy (bolus 5-FU before and after PVI + XRT vs. PVI before, during, and after XRT vs. biochemically modulated bolus 5-FU and XRT): mature outcome results and pelvic failure analysisInt J Radiat Oncol Biol Phys60137138CrossRef
21.
Zurück zum Zitat Kim, DY, Jung, KH, Kim, TH, et al. 2006Does capecitabine improve tumor response more effectively than 5-fluorouracil/leucovorin in preoperative chemoradiotherapy for locally advanced rectal cancer? Comparative analysis of two prospective phase II trialsJ Korean Soc Coloproctol22102 Kim, DY, Jung, KH, Kim, TH,  et al. 2006Does capecitabine improve tumor response more effectively than 5-fluorouracil/leucovorin in preoperative chemoradiotherapy for locally advanced rectal cancer? Comparative analysis of two prospective phase II trialsJ Korean Soc Coloproctol22102
22.
Zurück zum Zitat Kim, DW, Kim, DY, Kim, TH, et al. 2006Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer?Cancer10616941700PubMedCrossRef Kim, DW, Kim, DY, Kim, TH,  et al. 2006Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer?Cancer10616941700PubMedCrossRef
23.
Zurück zum Zitat Kim, JC, Kim, TW, Kim, JH, et al. 2005Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancerInt J Radiat Oncol Biol Phys63346353PubMedCrossRef Kim, JC, Kim, TW, Kim, JH,  et al. 2005Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancerInt J Radiat Oncol Biol Phys63346353PubMedCrossRef
24.
Zurück zum Zitat Bosset, JF, Calais, G, Mineur, L, et al. 2005Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921J Clin Oncol2356205627PubMedCrossRef Bosset, JF, Calais, G, Mineur, L,  et al. 2005Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921J Clin Oncol2356205627PubMedCrossRef
25.
Zurück zum Zitat Losi L, Luppi G, Gavioli M, et al. Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis 2005;1–7. Losi L, Luppi G, Gavioli M, et al. Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis 2005;1–7.
26.
Zurück zum Zitat Thames, HD,Jr, Peters, LJ, Withers, HR, et al. 1983Accelerated fractionation vs. hyperfractionation: rationales for several treatments per dayInt J Radiat Oncol Biol Phys9127138PubMed Thames, HD,Jr, Peters, LJ, Withers, HR,  et al. 1983Accelerated fractionation vs. hyperfractionation: rationales for several treatments per dayInt J Radiat Oncol Biol Phys9127138PubMed
27.
Metadaten
Titel
Preoperative Chemoradiotherapy with Concomitant Small Field Boost Irradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Phase II Study (KROG 04-01)
verfasst von
Dae Yong Kim, M.D.
Tae Hyun Kim, M.D.
Kyung Hae Jung, M.D.
Hee Jin Chang, M.D.
Seok-Byung Lim, M.D.
Hyo Seong Choi, M.D.
Seung-Yong Jeong, M.D.
Taek-Keun Nam, M.D.
Seong Yeob Ryu, M.D.
Doo Suk Lee, M.D.
Sung Il Choi, M.D.
Jin Hyung Kang, M.D.
Sei-Chul Yoon, M.D.
Publikationsdatum
01.11.2006
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 11/2006
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-006-0678-z

Weitere Artikel der Ausgabe 11/2006

Diseases of the Colon & Rectum 11/2006 Zur Ausgabe

Selected Abstracts

Selected Abstracts

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.